Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss.
Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo.
https://pubmed.ncbi.nlm.nih.gov/36089112/
Related Content
Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular...
VIEW RESOURCEThe Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...
VIEW RESOURCE